To further investigate the anti-MM effects of PTC-209, we tested the effects on the viability of CD138+ malignant PCs purified from newly diagnosed (patients 1–4) or relapsed patients (patients 5–11) in response to 72 hours treatment with a range of PTC-209 concentrations (Figure 1B). This evidence concerns the gene SDC1 and Miyoshi myopathy.